Tavilermide is under clinical development by Mimetogen Pharmaceuticals and currently in Phase III for Keratoconjunctivitis Sicca (Dry Eye). According to GlobalData, Phase III drugs for Keratoconjunctivitis Sicca (Dry Eye) have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Tavilermide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tavilermide overview
Tavilermide (MIM-D3) was under development for the treatment of keratoconjunctivitis sicca (dry eye syndrome). The drug candidate is administered into the eye topically as solution. It acts by targeting neurotrophic tyrosine kinase receptor 1 (TrkA or NTRK1).
Mimetogen Pharmaceuticals overview
Mimetogen Pharmaceuticals (Mimetogen) is a clinical stage biotechnology company that develops peptidomimetics for the treatment of ophthalmic diseases. The company develops small molecule drugs that imitate the functioning of neurotrophins in maintaining the wellness and development of various cells and tissues found in the eye. Its lead compound, tavilermide (MIM-D3), is a proteolytically stable, cyclic peptidomimetic partial TrkA receptor agonist, which induces the production of mucin in protecting ocular surface in dry eye syndrome. With its novel approach, the company develops solutions for other ophthalmological indications including glaucoma and other degenerative conditions of the retina such as retinitis pigmentosa. The company has offices in Canada and the US. Mimetogen is headquartered in Montreal, Quebec, Canada.
For a complete picture of Tavilermide’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
